Division of Infectious Diseases

Beating Biofilms

By: Kelly Cawcutt, MD, MS, FACP, FIDSA. Originally posted with CloroxPro, linked below.

Biofilms play an important role in the development of hospital-acquired infections (HAIs). In my line of work, I’m often reminded of their presence when handlining central venous catheters or endotracheal tubes, but biofilms can also be present on any environmental surfaces. Biofilms are defined as a complex collection of microorganisms that attach to a surface and create a surface specific ecosystemic on that surface (known as an extracellular polymeric substance [EPS]). Given the complexity, and strong adherence to surfaces, biofilms result in a perpetual conglomerate of microorganisms that may be impossible to fully eradicate, resulting in a difficult, albeit often underestimated cause of infections in healthcare.

Given the increase usage of ventilators for the treatment of severe COVID patients, I thought now was a particularly good time to drive awareness about this complex, Jello-like matrix filled with micro-organisms such as bacteria.

Biofilms contribute to many infectious diseases. Some classic examples are endocarditis, prosthetic joint infections and Clostridioides difficile (C. diff) along with device-related infections such as central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs) and ventilator-associated pneumonia (VAP), among others. In the era of COVID-19, the impact of biofilms on HAIs may be more prominent due to the high device utilization in the intensive care units (ICUs) and long length of stays.

Considering the impact of biofilms, there are many details to consider. First, given the capacity for biofilms to form on any surface, preventing microorganisms from attaching to a surface is a key intervention. The prevention of infection is multifaceted, and echoes the importance of infection control measures such as hand hygiene, device stewardship, aseptic technique, maintenance of devices and equipment, and environmental cleaning. Beyond this, patients may have additional risk factors that contribute to their likelihood of biofilm development which can include diabetes, kidney disease and immunosuppression. The risk factors are associated with decreased innate immune responses that normally fight the development of biofilms, so when a disease impacting the innate immune system is present, there is less of our individual capacity to prevent the build-up of that ‘gunk’ on my patient’s endotracheal tube. Recognizing the role comorbid conditions, especially those that are very common (like diabetes and kidney disease) may play in such infections is essential as we strive to beat biofilms and prevent HAIs.

There are many human pathogens that are described to comprise, and grow within, biofilms can result in infection, including, but not limited to, Staphylococcus aureus, Pseudomonas aeruginosa, Legionella pneumophila. Candida species, including both Candida albicans and Candida auris (C. auris), are known to also cause biofilms. The known presence of these organisms has resulted in innovative devices, such as central venous catheters, impregnated with antimicrobial agents to prevent microbial attachment to the catheter, and therefore biofilm development. Such catheters have demonstrated decreases in HAIs, specifically in this scenario, CLABSI.

Although individual patient infection control measures must be followed, environmental sources of biofilm cannot be ignored. One specific rising concern in the infection control world is C. auris, which was first detected in 2009, and subsequently has spread throughout the world. Infections secondary to C. auris are significant due the life-threatening nature of these infections, combined with both the resistance to several antifungal medications and the capacity to spread within healthcare facilities. C. auris has been described to cause surface biofilms in patient rooms that may be difficult to eradicate, therefore be a conduit for infections. C. auris may be contracted from a patient, or their environment (including equipment that may be used for multiple patients), in as little as 4 hours, therefore effective disinfection is critical. Chlorhexidine-based regimens for patient asepsis may not be as effective as povidone iodine and environmental disinfectants, such as ethyl alcohol and quaternary ammonium, may be less effective than hydrogen peroxide or sodium hypochlorite. We must understand which infection control strategies, including the chemicals used, are effective against pathogens, or we will miss the opportunity to prevent HAIs!

Beyond the patient and physical environment, biofilms with infectious pathogens (such as Pseudomonas aeruginosa and Legionella pneumophilia) can form in water sources and clear guidance exists from the CDC on how to assess, and decrease the risk, of water-based biofilm as a source for transmission of infection within hospitals. Examples of where such biofilms could occur is within faucets, ice machines, showers, toilets and drains.

Given the near impossibility of eradicating biofilms, further research into prevention of biofilms is of paramount importance. Specifically, the roles of antimicrobial impregnated devices and surfaces (such as the central venous catheter device mentioned above), and optimal patient asepsis and environmental disinfection. Our best offense continues to be adherence to infection control practices and engaging the entire healthcare team in the one-two punch required to beat biofilms. Our patients are depending on us!

Find the full original post here: https://www.cloroxpro.com/blog/infections-inside-out-beating-biofilms/

UNMC ID at #CROI 2021

Conferences may continue to look different due to the COVID-19 pandemic, but our ID faculty remain dedicated as ever to continuing to contribute to scientific knowledge and advancement of patient care. The Conference on Retroviruses and Opportunistic Infections (CROI) was held this year from March 6-10, and UNMC had several presentations. See below for the highlights and check out the conference for more details!

130 RIFAPENTINE +/– MOXIFLOXACIN FOR PULMONARY TUBERCULOSIS INPEOPLE WITH HIV April Pettit, Payam Nahid, Patrick P. Phillips, Andrew Vernon, Ekaterina Kurbatova, Rodney Dawson, Ian Sanne, Ziyaad Waja, Lerato Mohapi, Wadzana,Samaneka, John Johnson, Susan Dorman, Richard E. Chaisson, Susan Swindells, for TBTC Study 31/ACTG 5349 study team

178 ADVERSE PREGNANCY OUTCOMES AMONG HIV-INFECTED WOMEN EXPOSED TO ISONIAZID IN BRIEF-TB Amita Gupta, Michael Hughes, Jorge T. Leon-Cruz, Anchalee Avihingsanon, Noluthando Mwelase,Patrice Severe, Ayotunde Omoz-Oarhe, Gaerolwe Masheto, Laura Moran, Constance A. Benson,Richard E. Chaisson, Susan Swindells, for the ACTG 5279 BRIEF TB Trial

505 WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIAL Parul Patel, Ronald D’Amico, Shanker Thiagarajah, Sterling Wu, Emilie Elliot, Joseph W. Polli, Ojesh Upadhyay, Rodica Van Solingen-Ristea, Chloe Orkin, E. Turner Overton, Susan Swindells, Jean A. Van Wyk, Matthew Bosse, Vani Vannappagari

91 PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375 Kimberly K. Scarsi, Laura M. Smeaton, Anthony T. Podany, Maxine Olefsky, Elizabeth Woolley, Elizabeth Barr, Kayla Campbell, Sivaporn Gatechompol, Jeffrey Jeppson, Sajeeda Mawlana, Khuanchai Supparatpinyo, Catherine Godfrey, Susan E. Cohn, Rosie Mngqibisa, for the AIDS Clinical Trials Group A5375 Study Team

368 PHARMACOKINETICS OF 2 CONTRACEPTIVE IMPLANTS AMONG WOMEN ON RILPIVIRINE-BASED ART Shadia Nakalema, Catherine A. Chappell, Michelle Pham, Ritah Nakijoba,Leah Mbabazi, Pauline Byakika-Kibwika, Julian Kaboggoza, Stephen I. Walimbwa, Jeffrey Jeppson, Lee Winchester, Marco Siccardi, Courtney V. Fletcher, Kimberly K. Scarsi, Mohammed Lamorde

359 PERSISTENT HIV TRANSCRIPTION AND VARIABLE ARV LEVELS IN LYMPH NODES DURING ART Courtney V. Fletcher, Eugene Kroon, Timothy Schacker, Suteeraporn Pinyakorn, Nicolas Chomont, Suthat Chottanapund2, Peeriya Prueksakaew, Khunthalee Benjapornpong, Supranee Buranapraditkun, Jintanat Ananworanich, Sandhya Vasan, Denise C. Hsu, for the RV254/SEARCH 010 Study Group

undefined

Combatting COVID-19 vaccine hesitancy among people with HIV

Nichole N  Regan, APRN-NP

Content written by Specialty Care Center Nurse Practitioner, Nikki Regan, APRN

The Nebraska Medicine Specialty Care Center provides primary and specialized care to over 1100 people with HIV (PWH) in the Nebraska and southwest Iowa region.

At the onset of the COVID-19 pandemic in March 2020, PWH expressed a variety of emotions and concerns. Most were afraid that their HIV status would increase risk of contracting COVID-19, or suffering from severe illness or death (based on early and limited data, it appears that PWH who are on effective therapy have the same risk for COVID-19 infection as people who do not have HIV). Our phones were overrun by patients cancelling appointments, strictly quarantining and afraid to leave their homes for any reason. Notably, many of our patients 55 years and older stepped forward, proud to be a symbol of survivorship, after experiencing the early HIV epidemic of the 1980s firsthand.

It is no surprise then that the advent and growing availability of COVID-19 vaccinations in 2021 has been met with a mix of emotions for PWH. Patients in general have expressed concern about the speed with which the Moderna and Pfizer vaccines were developed. The concept of mRNA delivery was previously unheard of to the general public. More specifically, our patients want to know if it is safe for them to receive the vaccine since they have HIV. Vaccine hesitancy may be higher among people of color, rooted in generations of structural racism resulting in medical mistreatment without proper informed consent. (Approximately one-third of patients at the Specialty Care Center identify as non-White). Finally, even patients who were eager to receive the COVID-19 vaccine were disappointed to learn that they will not be vaccinated in our clinic, since vaccinations are being managed by state and local health departments instead of hospitals and clinics.

The team at the Specialty Care Center has quickly mobilized a plan to promote acceptance of COVID-19 vaccinations for PWH in our community. Originating with the creation of a COVID-19 Task Force in January 2021, clinic champions have led several projects including the development of a COVID-19 FAQ handout for patients in both English and Spanish, a bulletin board in the patient waiting area displaying pictures and statements from staff as to why they chose to receive the vaccine, and a plan to actively discuss our recommendation to receive the COVID-19 vaccine with every patient in our care.

“Why I got the shot” vaccine bulletin board with testimonials from clinicians and staff at the specialty care center

With each clinic interaction, patients are offered assistance in pre-registering for the COVID-19 vaccine online, via www.vaccinate.ne.gov if they live in Nebraska. Patients from Southwest Iowa are also encouraged to contact their state and local health departments for direction. Additionally, clinic champions are contacting patients at home via telephone and One Chart Patient portal, and completing pre-registrations in that manner. Those patients 65 and older have been assisted with scheduling their vaccine appointment in their designated county of residence. Additionally, CARES Act funding has been earmarked to assist with transporting qualified patients to and from vaccine appointments.

This Nebraska Medicine FAQ site has more information about the COVID-19 vaccines.

Bottom line: people with HIV CAN and SHOULD receive the COVID-19 vaccine, in consultation with their clinician. To learn more, or to pre-register in the state of Nebraska, visit www.vaccinate.ne.gov.

Clinical Consequences of Contaminated Blood Cultures in Adult Hospitalized Patients at an Institution Utilizing a Rapid Blood-Culture Identification System

Dr. Mark Rupp; senior author and Division Chief for @UNMC_ID

Blood culture contamination results in prolonged hospital length of stay, inappropriate use of antibiotics, and increased cost as well as the associated adverse events such as falls, drug errors, and healthcare associated infections (adverse events that may occur during more prolonged hospital stay) and emergence of antibiotic resistance, C. difficile infection, and antibiotic side effects (adverse events associated with unnecessary antibiotic administration).

However, nearly all studies indicating the harm associated with blood culture contamination were performed in the era prior to the use of rapid, molecular-based blood culture identification systems. In many instances, with use of rapid blood culture ID systems, true pathogens can be differentiated from likely contaminants (e.g. Staphylococcus aureus versus coagulase-negative staphylococci) very quickly. The effect of rapid blood culture ID systems on the clinical importance of blood culture contamination is not well described.

Therefore, we performed a large retrospective cohort study comparing outcomes between hospitalized patients with blood culture contamination and those with sterile blood cultures – during a time period when a rapid blood culture identification system (Biofire FilmArray Blood Culture Identification) was in routine use.

From June 1, 2014 to December 31, 2016, 19,255 patients were admitted to the hospital who had blood cultures performed. After excluding pediatric age patients, patients with true bacteremia, patients with repeated admissions, and those with equivocal results, we analyzed outcomes in 11,010 patients with sterile cultures and 464 with contaminated cultures. Primary outcomes of interest were hospital length of stay and antibiotic use. Variables potentially affecting outcome were examined and included socio- demographic factors (age, gender, race, marital status, medical insurance status) and various comorbid conditions including smoking, alcohol use, BMI, COPD, CKI, cirrhosis, and diabetes. Additional factors examined included ICU stay, admission from the emergency department, and location of blood draw (peripheral vein versus central venous catheter).

Univariate and multivariate analysis was conducted using generalized linear models. Forward stepwise selection was utilized to create the final model and Akaike information criterion value was used to assess model fit.

Bottom line, after controlling for age, gender, race, BMI, comorbid conditions, and hospital factors, blood culture contamination was associated with nearly a full extra day (0.8 days) of hospital stay (P= 0.032) and nearly a full day (0.8 days) of unneeded antibiotics (P= 0.011).

Previous studies have noted the adverse effect of blood culture contamination on clinically important outcomes, and in general, previous investigators noted a greater effect then was noted in our study. The decreased negative effect may be due to the use of rapid blood culture identification systems and the presence of a robust antimicrobial stewardship program at our institution.

Therefore, despite the use of molecular-based rapid blood culture identification systems and well-functioning antimicrobial stewardship programs, blood culture contamination continues to adversely impact patient outcomes – resulting in significantly prolonged hospital stay and unnecessary use of antibiotics. Efforts to minimize blood culture contamination continue to be justified and needed!

Sidra Liaquat MBBS, MSc, Lorena Baccaglini PhD, DDS, Gleb Haynatzki PhD, DSc, Sharon J. Medcalf PhD and Mark E. Rupp MD

Infection Control & Hospital Epidemiology (2020), 1–7. doi:10.1017/ice.2020.1337

https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/clinical-consequences-of-contaminated-blood-cultures-in-adult-hospitalized-patients-at-an-institution-utilizing-a-rapid-bloodculture-identification-system/F0B57309C6FB8464591E5CAC7E37C926

undefined

https://twitter.com/UNMC_ID?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

We are HIRING! Unique Community ID Opportunity Tailored to Your Professional Interests

Here @UNMC_ID we are always excited for the opportunity to grow our Division, and below you will find our announcement of a new position we have!

The Division of Infectious Diseases at the University of Nebraska Medical Center in Omaha, NE is recruiting a Community ID physician to join our growing faculty.  This opportunity can be customized to fit your professional interests – whether clinical, academic, research or combination at an internationally recognized ID program of excellence.

The Division is a robust group comprised of 26 ID physicians, as well as APP’s and clinical and research support staff. We provide full spectrum infectious disease care at our clinical partner, Nebraska Medicine.   Members of the department pursue specialty interests in all areas of infectious disease. We also have an academic mission with our fellowship program and graduate medical education. 

Opportunity Highlights:

  • Provide ambulatory tele-ID consultation services in several communities across Nebraska
  • Collaborative activities with the ICAP/ASAP Program to offer infection control and antimicrobial stewardship guidance to healthcare facilities across Nebraska
  • Inpatient and outpatient care
  • Abundant clinical opportunities and/or research with protected time and support

The successful candidate must be an MD/DO (or equivalent degree) who is board certified/eligible in Infectious Diseases with excellent clinical skills and enthusiasm for patient care, teaching, and/or clinical research. Our compensation package is extremely competitive.  In addition, comprehensive benefits and relocation assistance are offered. Academic rank is dependent on qualifications. Individuals from diverse backgrounds are encouraged to apply – https://unmc.peopleadmin.com/postings/53864

Learn more:

UNMC ID –  https://www.unmc.edu/intmed/divisions/id/index.html

ID blog – https://blog.unmc.edu/infectious-disease/feed/

undefined

Infections Inside Out: Focus on Hospital-Acquired Infections

By: Kelly Cawcutt, MD, MS, FACP, FIDSA; Sponsored by Clorox Healthcare

Hospital-acquired infections (HAIs) are infections acquired during medical care and are often directly related to the use of medical devices or procedures, along with lapses in critical infection control practices such hand hygiene, and appropriate cleaning and disinfection. Every day in the US, approximately 1 in 31 patients will suffer from a HAI. These infections can include central line associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSIs), ventilator-associated pneumonia (VAP) and development of Clostridiodes difficile infection (CDI). The Centers for Disease Control (CDC), along with State and county health departments, along with individual hospitals, monitor these closely via reports to the National Healthcare Safety Network, which assess outbreaks and monitors progress towards future prevention efforts – with a goal of elimination of HAIs in the future of medicine.

The impact of COVID-19 on HAIs may ultimately be profound due to the use of antibiotics for possible bacterial co-infection and prolonged ICU stays, including the use of multiple invasive devices placing these vulnerable patients at risk for CLABSI, CAUTI, VAP, CDI. Additional factors clearly impacting HAIs in during this pandemic include lack of appropriate resources and supply chain issues (such as personal protective equipment and testing supplies), combined with varying rates of infected healthcare workers and risk of burnout impacting the available workforce. Finally, there is ongoing concern that fear amidst this pandemic may negatively impact adherence to infection control practices.  Never has prevention of HAIs been more critical given the burden of COVID-19 on healthcare around the world. 

Prevention of HAIs

Prevention of HAIs is comprised of several key concepts: avoid both device placement and antibiotic use unless clearly indicated, remove devices and stop antibiotics as soon as possible, and follow infection control measures for the healthcare workers and environment (such as standard and transmission-based precautions, hand hygiene and environmental and equipment cleaning).

With the clear impact of HAIs, there are several different guidelines focusing on how to prevent HAIs. A few critical recommendations and guidelines are:

Anyone within the healthcare field, including the patient, is accountable to help prevent HAIs. This is truly a multidisciplinary effort!

Patient’s role

In the end, we are all patients and, as mentioned above, can play a role in prevention of HAIs. There are several key actions anyone can take to keep ourselves, and our loved ones, safe from these infections. Practicing excellent hand hygiene, watching closely for signs of developing infection, remembering to only take antibiotics when your healthcare team feels it is necessary and remaining an advocate for safety throughout your hospital stay (such as reminding healthcare workers to perform hand hygiene). (Here is a quick video on five tips to prevent HAIs as a patient.)

Device-Related Risks

There are many invasive devices that are frequently used for patient care, and once they are in place for at least 48 hours, those devices carry the risk for a possible reportable HAI to develop. Some patients require infusions of medications or frequent access to blood draws and monitoring, therefore may have a central venous catheter placed, thereby creating a simultaneous risk for developing CLABSI. Certain patients will have trouble urinating, or need very close monitoring of urine output due to impaired kidney, so an indwelling urinary catheter is inserted and, with that, the risk for CAUTI arises. Patients with severe lung disease, such as those with respiratory failure from COVID-19, may require invasive mechanical ventilation, as provided via an endotracheal tube. Much like the two catheters listed above, with insertion and use of the endotracheal tube, the risk for development of VAP evolves.

In essence, all of these devices are inserted through a potential non-sterile source and therefore carry a risk for bacteria to create a biofilm on the external surface of the catheter, or have bacterial inoculated on the internal surface during cares, increasing the risk of a possible life-threatening HAI. Understanding appropriate indications, insertion techniques, maintenance and prompt removal, once no longer indicated,  is of paramount importance.

Environmental Cleaning

Infections can spread within the healthcare setting, including based on inadequate environmental cleaning. CDI is one such infection, which is highlighted below. Additionally, there are many aspects of the environment to consider, such as the high touch surfaces at risk for contamination based on lack of hand hygiene. Air-based contamination are based on infectious aerosols (which may additionally occur via coughing, sneezing, flushing a toilet, procedures for a patient that may generate aerosols such as suctional or intubation) or mold secondary to construction or other damage. Water-based contamination can be found in ice machines, faucets, drains and with equipment that utilizes water but is not maintained or cleaned via manufacturer instructions-for-use (IFUs).

All of these simple components around us can serve as conduits for infection. Although this may be top of mind for many during this pandemic and tempt us to focus only on COVID-19, the more ‘mundane’ aspects of environment infection control are just as important in 2020 as they were each year prior. It’s critical that healthcare team members, including nurses, doctors, technicians and  EVS staff  responsible for cleaning equipment, or the environment, use products that are EPA-registered to be effective against these HAIs.

Seeing C. diff Differently – What Has Changed in Prevention?

CDI is the most common cause of HAIs in the US, with specific guidelines for infection prevention given its prevalence from national societies (Infectious Diseases Society of America and the Society of Healthcare Epidemiology of America) and from the CDC. There are several key steps to preventing CDI as a HAI:

  • Antibiotic use is the primary driver for development of CDI, therefore it is imperative to follow antibiotic stewardship principles to minimize risk of development of CDI.
  • Implement contact precautions for those with confirmed or suspected infections, to avoid unintended spread to others.
  • Consider use of innovative engineering for improving adherence to isolation precautions with solutions such as the ‘Red Box.’
  • Maintain appropriate personal protective equipment with gowns, gloves and hand washing (especially in outbreak settings) to prevent spread of spores.
  • Confirm with appropriate testing strategies. This is key as colonization exists with this organism, so non-infectious etiologies should be considered, do not test if laxatives have been used in the last 48 hours, do not send solid stool for testing and remember that repeat testing for cure is not necessary.
  • If non-disposable equipment is used, dedicating equipment to the patient room should be done if possible. If there is an inadequate equipment supply, cleaning before and after each patient use should be done.  For CDI, even if using a 2-in-1 product, cleaning should occur prior to disinfecting and should be completed with a  compatible sporicidal disinfectant (EPA List K agents; such as Bleach Germicidal Wipes) should be utilized.
  • Terminal room cleaning for patient rooms in which C. diff was present is also critical to prevent ongoing spread of infection as the spores can survive for months within the hospital room and many standard disinfectants are ineffective, therefore effective disinfection is critically important, especially during outbreak situations. Methods may include cleaners, such as Bleach Germicidal Disinfectants.

Despite all the efforts on COVID-19, as frontline healthcare teams, we must all pitch in to continue the fight against HAIs. Our patients are depending on us.

Full original post can be found here: https://www.cloroxpro.com/blog/infection-inside-out-focus-on-hospital-acquired-infections/

Infections Know No Bounds – The Reality of Infections in Healthcare Facilities

By: Kelly Cawcutt, MD, MS, FACP, FIDSA; Sponsored by Clorox Healthcare

Infectious diseases remain a critical cause of morbidity, mortality and cost in all healthcare facilities including outpatient clinics, long-term care facilities and acute care facilities, such as hospitals. Infections can come from two main places – inside the hospital walls and from outside within a community. A patient can develop a community-acquired infection prior to arrival in any healthcare setting, which often is what prompted the patient to seek care. The most recent example of this is COVID-19 (SARS-CoV-2). This virus is impacting healthcare facilities around the world with increased patient burdens and human-to-human spread in which infected patients are transmitting the infection to other patients, visitors and healthcare workers.

There are also many healthcare-associated infections (HAIs) that patients in both acute and long-term care settings are at specific risk for based on multiple factors such as: having chronic medical problems that increase possible risks (such as requiring dialysis or conditions causing weakened immune systems), prior admission to healthcare facilities or receipt of antibiotics (placing patients at increased risk of acquisition of antibiotic-resistant (AR) infections or Clostridiodes difficle (C.diff) infection), the use of invasive devices (such as a ventilator in the setting of respiratory failure), and any procedures (such as surgery) needed for medical care. Lapses in infection control practices such as hand hygiene and cleaning and disinfection are another HAI risk factor. Going forward, we will specifically focus on HAIs in acute healthcare settings. This is the first post in a blog series originally published for Clorox Healthcare, in which we’ll be diving further into HAIs.

The primary reported infections under the umbrella of HAIs include central line associated bloodstream infections (CLABSI), catheter associated urinary tract infections (CAUTI), and surgical site infections (SSIs) and ventilator associated pneumonia (VAP), and C. diff gastroenteritis (actually the leading cause of HAI). These HAIs are reported and tracked nationally by the National Healthcare Safety Network (NHSN). However, it is important to note that these infections can be caused by both antibiotic-susceptible and AR pathogens. According to the CDC, each year in the U.S., there are over 2.8 million infectious causes by AR pathogens. This results in over 35,000 deaths. Microorganisms that are frequently also discussed in this category include C. diff infections and detection of AR bacteria, such as Carbapenem-resistant Enterobacteriaceae (CRE) or Methicillin-resistant Staphylococcus aureus (MRSA). Prevention of these infections is clearly of paramount importance and infection control practices such as adherence to guidance for hand hygiene, isolation practices, when to wear gloves and gowns and environmental cleaning, to prevent spread throughout the hospital. Additional infection control expert guidance is available through many organizations including the CDC, Society for Healthcare Epidemiology of America (SHEA) and the Association for Professionals in Infection Control and Epidemiology (APIC).

The toll that infections can have on patients, and healthcare facilities as a whole, can be daunting when you consider the needs for ongoing surveillance, diagnosis, management and complex infection prevention strategies. Strategies for the prevention of HAIs nearly all start with maintaining excellent hand hygiene, minimizing unnecessary invasive devices, prudent and correct use of antibiotics, employing appropriate precautions to prevent spread of infection within a facility and correct and thorough environmental and equipment cleaning and disinfecting to help eliminate pathogens. In many ways, the strategies are easier said than done; however, they are important to helping prevent the spread of the pathogens that cause infection, especially when you consider the substantial cost, they have on patient health and hospital cost.

Over the next posts, we will break down some of the key aspects of infectious diseases and prevention in the acute healthcare setting, including AR, HAIs, biofilms, multi-drug resistant organisms and challenges of infection prevention. Together, we can all strive to better understand and improve infection prevention thereby improving patient safety and care.

Full post originally at https://www.cloroxpro.com/blog/infections-know-no-bounds-the-reality-of-infections-in-healthcare-facilities/

Virtual IDWeek – A First, and Memorable Experience

by UNMC ID First Year Fellow Dr. Jonathan Ryder

My first experience with IDWeek was nothing like I expected it to be (given its virtual nature), yet it provided a fantastic experience, full of learning opportunities from the world’s experts. First, I will comment that we are fortunate at UNMC infectious diseases fellowship to be provided protected time to attend IDWeek as first year fellows. Being able to access a highly educational event pays dividends down the road by hearing from content experts and seeing previews of novel diagnostics and antibiotics.

IDWeek 2020 kicked off with Fellows’ Day, in which we were able to learn about how other fellows cope with the COVID-19 pandemic, how the job market is shaping up in these unprecedented circumstances, and listen to some truly unusual and challenging cases from other fellows. The next day of IDWeek included the 24-hours of COVID-19 Chasing The Sun event, a whirlwind of COVID-19 information. Listening to Dr. Fauci speak was an amazing opportunity as well as learning about summaries of treatment options and controversies of transmission routes.

The rest of the week allowed for attendance of sessions electively to our areas of interest. My favorite sessions were on infectious complications in people who use intravenous drugs, the risk of infective endocarditis in bacteremia, and AmpC beta-lactamases. UNMC’s own Dr. Mark Rupp gave an enthralling SHEA lectureship that is highly recommended. I spent a lot of time learning about staphylococcal bacteremia and endocarditis, as these were areas I have encountered frequent questions as a first year fellow.

Overall, IDWeek 2020 was a success, even with it being my first virtual conference. The sessions had amazing speakers with high yield content. The part that I missed out on the most was opportunities for networking, arguably the most valuable part of a conference. I wish I could have met future mentors and other ID fellows. However, I was quite impressed with the organization and efficiency of the virtual conference. I look forward to attending ID Week 2021 in San Diego (hopefully) next year!

LIVE from #IDWeek2020, it’s UNMC ID!

IDWeek is our premier Infectious Diseases conference, and we are excited about it all year long. This year the anticipation is no different, although the conference itself will be very different because of COVID-19. This year is completely virtual, with a full 24hrs of #ChasingTheSun COVID coverage starting October 21, 2020. Many presentations are pre-recorded so we can access them at our leisure; posters are virtual with recorded voice-overs; there will be live Q&A with presenters throughout the week; and a few live sessions not to be missed! With thousands of registrants, our social media feeds are sure to be filled with #IDWeek2020 and we are here for it!

We want you to know where you can find UNMC ID faculty and trainees this week presenting and moderating, and follow us on twitter at @UNMC_ID!

Oral Presentations


Dr. Nada Fadul (Director of our Specialty Care Center) and Nikki Regan APRN will be co-presenting the #IDWeek2020 Program Committee Choice Award oral abstract: A Quality Management Project of a Midwestern Academic HIV Clinic Operation During COVID-19: Implementation Strategy and Preliminary Outcomes

Dr. Jasmine Marcelin will be presenting on October 22, 2020 12:30-1:45pm EDT/11:30-12:45pm CDT (on demand): Leading from the Minority – Strategies for Advancement for Members of Underrepresented Groups

Dr. Mark Rupp (Division Chief) will be presenting the SHEA Lectureship on October 23, 2020 9-9:30am EDT/8-8:30 CDT (on demand): When this is all over, and we are back to normal, it won’t be normal

Lt. Col. Dr. Elizabeth Schnaubelt will be presenting on October 23, 2020 10-11:15am EDT/9-10:15am CDT (on demand): Mitigating Harm’s Way: Innovations in Military/civilian ID Partnerships

Check out our posters

Presenter(s): Andrew Watkins, PharmD; Trevor Van Schooneveld MD; Scott Bergman, PharmD: Use of a Novel Clinical Decision Support Tool for Pharmacist-Led Antimicrobial Stewardship in Patients with Normal Procalcitonin

Presenter(s): Mark Ridder MD (2nd Yr Fellow); Kelly Cawcutt MD: The Buck Stops Here. PICC Line Utilization: Stewardship Is Not Only About Antimicrobials Any More

Presenter(s): Brett Young PharmD (Pharmacy Resident); Scott Bergman, PharmD; Nico Cortes-Penfield MD; Trevor Van Schooneveld, MD; Bryan Alexander, PharmD: Evaluation of addition of outpatient parenteral antimicrobial therapy and orthopedic ID resources to transitions-of-care outcomes

Presenter(s): Claire Ferguson (Medical Student); Scott Bergman, PharmD; Jennifer Cavalieri; Mark Rupp, MD; Trevor Van Schooneveld, MD; Salman Ashraf MD: Assessment of the Long-Term Effects of Training Consultant Pharmacists to Promote Antimicrobial Stewardship in Long-Term Care Facilities 

Co-Author: Nico Cortes-Penfield MD: Impact of #idjclub, a synchoronous twitter journal club, as a novel Infectious Disease education platform

Co-Author: Jasmine Marcelin, MD: In their own words: a Qualitative Analysis of Factors Contributing to Gender Bias in Academic Advancement in Infectious Disease

Presenter(s): Mackenzie Keintz MD (IM Resident); Jasmine Marcelin, MD, Bryan Alexander PharmD, Trevor Van Schooneveld MD, Scott Bergman PharmD, Erica Stohs MD: Impact Of Clinician Specialty on the Use of Oral Antibiotic Therapy for Definitive Treatment of Uncomplicated Bloodstream Infections

Co-Author: Jonathan Ryder (1st yr ID Fellow): A Retrospective Cohort Study of Treatment Patterns and Clinical Outcomes in Patients with COVID-19

Co-Author: Jasmine Marcelin MD: Equity in academic advancement: findings from an IDSA-sponsored survey of infectious disease physicians

Presenter(s): Bryan Alexander PharmD; Trevor Van Schooneveld MD; Scott Bergman PharmD; Nico Cortes-Penfield MD: Significant Institutional Cost Savings from OPAT-Facilitated Discharge for Patients with Challenging Situations

Presenter(s): Clayton Mowrer MD (2nd Yr ID Fellow); Erica Stohs MD, Trevor Van Schooneveld MD: Evaluation of Surgical Site Infections in Solid Organ Transplant Recipients with Beta-Lactam Allergies

Presenter(s): Wilfredo Lopez (medical student); Sara Bares MD; Nada Fadul MD: Lung Cancer Screening in at-risk patients with HIV in a Midwestern Clinic

Co-Author: Trevor Van Schooneveld: #BeASteward: Transforming Infectious Diseases Fellows Into Antimicrobial Stewards Using the IDSA Antimicrobial Stewardship Curriculum

Presenter(s): Jasmine Marcelin MD; Kelly Cawcutt MD: Trends in Speaker Representation at the Infectious Diseases Society of America (IDSA) ID Week Conference, 2013-2019

Presenter(s): Casey Zelus MD (1st yr ID Fellow); Andre Kalil MD; Trevor Van Schooneveld MD; Jasmine Marcelin MD; Kelly Cawcutt MD: Pneumonia due to Co-Infection in the ICU: Detection and Clinical Significance

Congratulations to all of our presenters, and we hope everyone enjoys #IDWeek2020!

Welcoming our New Infectious Diseases PGY-2 Pharmacy Resident

We are excited to welcome Molly Miller PharmD as a new PGY-2 in our ID Pharmacy Residency Program! She’s the second ID Pharmacy resident we have had and a fantastic addition to our team! Read on to learn a little more about her…

Dr. Miller with a cute baby goat!

Tell us about the position you recently started
I recently started as a second-year pharmacist resident specializing in infectious diseases. This year I will dive deeper into the complexities of infectious diseases and their treatments through rounding with the inpatient infectious diseases consult services (including general, orthopedic, oncology, transplant, and pediatric infectious diseases), acting as part of the Antimicrobial Stewardship Program, and participating in various outpatient and outreach activities, including HIV clinic, the Outpatient Parenteral Antimicrobial Therapy (OPAT) program, and community outreach stewardship.

Tell us about your background
I grew up in rural Nebraska on an acreage with my family (and lots of farm animals) and graduated from Arlington High School. I completed my undergraduate degree in chemistry at the University of Nebraska-Lincoln and went on to obtain my Doctor of Pharmacy degree from the University of Nebraska Medical Center. I completed my Post Graduate Year 1 (PGY1) pharmacy residency at Nebraska Medicine. You could say I bleed Husker red.

Why did you choose to come work at UNMC
My training as a student and as a PGY1 pharmacy resident at Nebraska Medicine ignited my passion to continue my training as a PGY2 infectious diseases resident. The program here provides an excellent learning environment with the variety of ID consult teams and diverse patient populations. Here, I get to be an integral part of a rounding consult team and to work with some of the top infectious diseases clinicians in the nation who care not only about providing extraordinary patient care, but also about teaching and developing the next generation of infectious diseases clinicians. I also find the opportunity to train in an IDSA-designated Antimicrobial Stewardship Center of Excellence extremely valuable, as I have a strong passion for antimicrobial stewardship. The excellent preceptors and family atmosphere provided by the program create an unmatched environment in which to learn and grow, and I consider it the utmost privilege to have the opportunity to complete my training here. There truly is no place like Nebraska.

What makes you excited about working in ID
My passion for infectious diseases pharmacy has grown undeniably strong throughout my pharmacy training. I am fascinated by the complexity of infectious diseases and the associated treatment modalities. Each patient case is a unique puzzle to solve with many different pieces to carefully consider and fit into place. The field will constantly evolve as drug-resistant infections continue to emerge, necessitating the generation of new strategies and medications to treat these serious infections. This creates endless opportunities for pharmacists to exercise and develop their ingenuity and critical thinking skills, which I find extremely exciting.

Tell us something about yourself that is unrelated to medicine
I am an animal lover and enjoy spending time visiting my family and all the animals on my parents’ acreage on my free weekends. Someday I hope to have as many animals of my own (good thing my husband is a veterinarian), but for now we just have a mini Australian shepherd named Bella and an orange tabby cat named Boo.

Learn more about the Nebraska Medicine ID Pharmacy Residency Program here

ePcIUpuT G dX QuZDH YhlsQ